These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 1693784)

  • 1. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
    Maxon HR; Schroder LE; Thomas SR; Hertzberg VS; Deutsch EA; Scher HI; Samaratunga RC; Libson KF; Williams CC; Moulton JS
    Radiology; 1990 Jul; 176(1):155-9. PubMed ID: 1693784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
    Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
    J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhenium-188(Sn)HEDP for treatment of osseous metastases.
    Maxon HR; Schroder LE; Washburn LC; Thomas SR; Samaratunga RC; Biniakiewicz D; Moulton JS; Cummings D; Ehrhardt GJ; Morris V
    J Nucl Med; 1998 Apr; 39(4):659-63. PubMed ID: 9544677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
    Pirayesh E; Amoui M; Mirzaee HR; Tabei F; Rakhsha A; Kalantari BA; Shafiei B; Assadi M; Asli IN
    J Nucl Med Technol; 2013 Sep; 41(3):192-6. PubMed ID: 23918612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients.
    Zhang H; Tian M; Li S; Liu J; Tanada S; Endo K
    Cancer Biother Radiopharm; 2003 Oct; 18(5):719-26. PubMed ID: 14629820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases.
    Maxon HR; Thomas SR; Hertzberg VS; Schroder LE; Englaro EE; Samaratunga R; Scher HI; Moulton JS; Deutsch EA; Deutsch KF
    Semin Nucl Med; 1992 Jan; 22(1):33-40. PubMed ID: 1375400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases.
    Cheng A; Chen S; Zhang Y; Yin D; Dong M
    Cancer Biother Radiopharm; 2011 Apr; 26(2):237-44. PubMed ID: 21539455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
    de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
    Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
    Lange R; Overbeek F; de Klerk JM; Pasker-de Jong PC; van den Berk AM; Ter Heine R; Rodenburg CJ; Kooistra A; Hendrikse NH; Bloemendal HJ
    Nuklearmedizin; 2016 Sep; 55(5):188-95. PubMed ID: 27443809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
    de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
    J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
    J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic radionuclide therapy in pain palliation.
    Liepe K; Runge R; Kotzerke J
    Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
    J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer.
    van der Poel HG; Antonini N; Hoefnagel CA; Horenblas S; Valdes Olmos RA
    Urol Int; 2006; 77(1):50-6. PubMed ID: 16825816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
    Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA
    J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
    Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
    Biersack HJ; Palmedo H; Andris A; Rogenhofer S; Knapp FF; Guhlke S; Ezziddin S; Bucerius J; von Mallek D
    J Nucl Med; 2011 Nov; 52(11):1721-6. PubMed ID: 21976530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
    Küçük NO; Ibiş E; Aras G; Baltaci S; Ozalp G; Bedük Y; Canakci N; Soylu A
    Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.